ATE319826T1 - Minimale promotoren und ihre verwendung - Google Patents

Minimale promotoren und ihre verwendung

Info

Publication number
ATE319826T1
ATE319826T1 AT99960139T AT99960139T ATE319826T1 AT E319826 T1 ATE319826 T1 AT E319826T1 AT 99960139 T AT99960139 T AT 99960139T AT 99960139 T AT99960139 T AT 99960139T AT E319826 T1 ATE319826 T1 AT E319826T1
Authority
AT
Austria
Prior art keywords
promotors
minimum
reagents
methods
promoter sequences
Prior art date
Application number
AT99960139T
Other languages
German (de)
English (en)
Inventor
James T Fuller
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22302848&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE319826(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Application granted granted Critical
Publication of ATE319826T1 publication Critical patent/ATE319826T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
AT99960139T 1998-10-19 1999-10-19 Minimale promotoren und ihre verwendung ATE319826T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10487198P 1998-10-19 1998-10-19

Publications (1)

Publication Number Publication Date
ATE319826T1 true ATE319826T1 (de) 2006-03-15

Family

ID=22302848

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99960139T ATE319826T1 (de) 1998-10-19 1999-10-19 Minimale promotoren und ihre verwendung

Country Status (14)

Country Link
US (1) US20070009487A1 (fr)
EP (1) EP1123396B1 (fr)
JP (1) JP2002527527A (fr)
AT (1) ATE319826T1 (fr)
AU (1) AU766005B2 (fr)
CA (1) CA2347369A1 (fr)
CY (1) CY1105034T1 (fr)
DE (1) DE69930294T2 (fr)
DK (1) DK1123396T3 (fr)
ES (1) ES2259846T3 (fr)
IL (2) IL142680A0 (fr)
NZ (1) NZ511798A (fr)
PT (1) PT1123396E (fr)
WO (1) WO2000023592A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE285806T1 (de) 1999-10-11 2005-01-15 Felton International Inc Universelle antiinfektionsschutzvorrichtung für nadellose injektoren
US7887506B1 (en) 1999-11-23 2011-02-15 Pulse Needlefree Systems, Inc. Safety mechanism to prevent accidental patient injection and methods of same
BRPI0415204A (pt) 2003-10-10 2006-12-05 Powderject Vaccines Inc construção de ácido nucleico, métodos de obtenção da expressão em células de mamìferos de um polipeptìdeo de interesse, e de imunização com ácido nucleico, partìculas revestidas, receptáculo de dosagem para um dispositivo de liberação mediada por partìculas, dispositivo de liberação mediada por partìculas, e, sequência de promotor quimérico isolada purificada
US20240123086A1 (en) * 2021-02-24 2024-04-18 University Of Massachusetts Inducible single aav system and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100792A (en) * 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4629782A (en) * 1984-12-21 1986-12-16 Syntex (U.S.A.) Inc. Crystalline form of N-acetylmuramyl-L-α-aminobutyryl-D-isoglutamine
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5047237A (en) * 1985-09-06 1991-09-10 Prutech Research And Development Partnership Attenuated pseudorabies virus having a deletion of at least a portion of a gene encoding an antigenic, nonessential protein, vaccine containing same and methods of identifying animals vaccinated with the vaccine
US5120657A (en) * 1986-12-05 1992-06-09 Agracetus, Inc. Apparatus for genetic transformation
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
GB8717430D0 (en) * 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5179022A (en) * 1988-02-29 1993-01-12 E. I. Du Pont De Nemours & Co. Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1991007487A1 (fr) * 1989-11-16 1991-05-30 Duke University Transformation de cellules tissulaires animales a l'aide de particules
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5204253A (en) * 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5149655A (en) * 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
US5558644A (en) * 1991-07-16 1996-09-24 Heartport, Inc. Retrograde delivery catheter and method for inducing cardioplegic arrest
US5658892A (en) * 1993-01-15 1997-08-19 The General Hospital Corporation Compound delivery using high-pressure impulse transients
TW360548B (en) * 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
US5888981A (en) * 1993-06-14 1999-03-30 Basf Aktiengesellschaft Methods for regulating gene expression
CN1112943C (zh) * 1994-01-21 2003-07-02 粉剂注射疫苗股份有限公司 气体驱动的基因送递装置
US5899880A (en) * 1994-04-08 1999-05-04 Powderject Research Limited Needleless syringe using supersonic gas flow for particle delivery
GB9502879D0 (en) * 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
FR2735789B1 (fr) * 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
US6013050A (en) * 1995-10-20 2000-01-11 Powderject Research Limited Particle delivery
GB9605690D0 (en) * 1996-03-19 1996-05-22 Oxford Biosciences Ltd Particle delivery
US5891718A (en) * 1996-03-27 1999-04-06 Vical Incorporated Tetracycline inducible/repressible systems
US6156567A (en) * 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
AU719629B2 (en) * 1996-11-08 2000-05-11 Oklahoma Medical Research Foundation Endothelium specific expression regulated by EPCR control elements
WO1998037185A2 (fr) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vecteurs pour expression genique regulee
US6368825B1 (en) * 1998-08-10 2002-04-09 Academia Sinica Baculovirus containing minimal CMV promoter

Also Published As

Publication number Publication date
AU766005B2 (en) 2003-10-09
EP1123396A2 (fr) 2001-08-16
US20070009487A1 (en) 2007-01-11
EP1123396B1 (fr) 2006-03-08
CA2347369A1 (fr) 2000-04-27
DK1123396T3 (da) 2006-07-10
PT1123396E (pt) 2006-07-31
DE69930294D1 (de) 2006-05-04
WO2000023592A3 (fr) 2000-07-27
WO2000023592B1 (fr) 2000-09-08
WO2000023592A2 (fr) 2000-04-27
WO2000023592A9 (fr) 2000-09-28
DE69930294T2 (de) 2006-11-02
AU1707300A (en) 2000-05-08
ES2259846T3 (es) 2006-10-16
IL142680A (en) 2010-04-15
NZ511798A (en) 2004-01-30
CY1105034T1 (el) 2010-03-03
IL142680A0 (en) 2002-03-10
JP2002527527A (ja) 2002-08-27

Similar Documents

Publication Publication Date Title
ATE551352T1 (de) Peptidakzeptorbindungsverfahren
DE69801321D1 (de) Slurrykohlenwasserstoffsyntheseverfahren mit mehrstufenkatalysatorwiederbelebung
DK0910633T3 (da) Hybrid polyketidsyntase I-gen
DE69828517D1 (de) Methode zur dns-isolierung.
FI962247A (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät
ATE188507T1 (de) Polyphenol oxidase gene
TR199802648A3 (tr) Gen tedavisi için nüklein asit yapilari.
ATE427959T1 (de) Gereinigtes sr-p70 protein
ATE319826T1 (de) Minimale promotoren und ihre verwendung
DE59814032D1 (de) Nucleinsäuremolekül, kit und verwendung
DE69811677D1 (de) Verfahren zur präparation von enantiomer-angereicherten, n-derivatisierten laktamen.
DE69733948D1 (de) In vivo herstellung von replicativen molekülen
EP0970192A4 (fr) ACIDE NUCLEIQUE CODANT UNE PROTEINE ALGU $i(M. TUBERCULOSIS)
EP1038025A4 (fr) Modifications genetiques associees au cancer
AU2001276385A1 (en) Nucleotide sequences which code for the lysr3 gene
DE59914061D1 (de) Das gen prv-1 und dessen verwendung
AR016145A1 (es) Citoquinas de mamifero; reactivos relacionados
ATE408686T1 (de) Chondrosarcom-assoziierte gene
DE29621775U1 (de) Auswechselbare Pläne, welche zur Information dienen
MX9709596A (es) Adn catal ??tico.
ATE53608T1 (de) Test fuer nukleinsaeuresequenzen, insbesondere genetische veraenderungen.
BR1100781B1 (pt) receptor quimÉrico proteinÁceo ligado À membrana celular, dna que codifica o mesmo, bem como vetor compreendendo o referido dna.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1123396

Country of ref document: EP